HeXun Biosciences Co's total inventories for the quarter that ended in Dec. 2025 was NT$6.0 Mil. HeXun Biosciences Co's average total inventories from the quarter that ended in Sep. 2025 to the quarter that ended in Dec. 2025 was NT$7.9 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. HeXun Biosciences Co's Net-Net Working Capital per share for the quarter that ended in Dec. 2025 was NT$9.07.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
HeXun Biosciences Co's Days Inventory for the
three
months ended in Dec. 2025 was 87.47.
Inventory Turnover measures how fast the company turns over its inventory within a year.
HeXun Biosciences Co's Inventory Turnover for the quarter that ended in Dec. 2025 was 1.04.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
HeXun Biosciences Co's Inventory-to-Revenue for the quarter that ended in Dec. 2025 was 0.09.
HeXun Biosciences Co (ROCO:6986) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
HeXun Biosciences Co's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2025 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
HeXun Biosciences Co's Inventory to Revenue for the quarter that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
HeXun Biosciences Co Total Inventories Related Terms
HeXun Biosciences Co Total Inventories Historical Data
* Premium members only.
The historical data trend for HeXun Biosciences Co's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HeXun Biosciences Co Total Inventories Calculation
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
HeXun Biosciences Co (ROCO:6986) has a Total Inventories of NT$6.0 Mil as of Dec. 2025. The total amount of inventory as recorded on a company's balance sheet. View historical data for HeXun Biosciences Co and its competitors.
Is HeXun Biosciences Co's Total Inventories too high?
HeXun Biosciences Co's current Total Inventories is NT$6.0 Mil. Overall, HeXun Biosciences Co has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does HeXun Biosciences Co's Total Inventories compare to VRTX and REGN?
HeXun Biosciences Co's Total Inventories of NT$6.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Biotechnology company?
A good Total Inventories depends on the Biotechnology industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for HeXun Biosciences Co and its competitors. HeXun Biosciences Co's current Total Inventories is NT$6.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HeXun Biosciences Co stock overvalued right now?
HeXun Biosciences Co (ROCO:6986) has a current Total Inventories of NT$6.0 Mil. The current Total Inventories is NT$6.0 Mil. HeXun Biosciences Co's overall GF Score™ is 23/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For HeXun Biosciences Co (ROCO:6986), the current Total Inventories is NT$6.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
HeXun Biosciences Co Ltd is engaged in the research and development of cell drugs and cell derivatives. It conducts research and development jointly with medical research institutions to use stem cells to treat cardiovascular, immune-inflammatory, and neurodegenerative diseases to develop innovative cell drugs and treatment methods. The company's main business items are new drug research and development, biotechnology services, and research and development services, such as: commissioned research and development and production services for cell medicine, agency testing and development services, and biomedical consulting services, etc.
23GF Score
Get the complete analysis for ROCO:6986
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6986 has been successfully added to your 
